Results 101 to 110 of about 95,392 (311)

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. [PDF]

, 2011
Despite its common use in nonmyeloablative preparative regimens, the pharmacokinetics of fludarabine are poorly characterized in hematopoietic cell transplantation (HCT) recipients and exposure-response relationships remain undefined.
Brunstein, CG, Cao, Q, Green, KG, Jacobson, PA, Long-Boyle, JR, McGlave, PB, Miller, JS, Rogosheske, J, Wagner, JE, Weisdorf, DJ   +9 more
core   +1 more source

PIEZO1 is Required for Acute Myeloid Leukemia Progression and Leukemia Stem Cell Maintenance via HIF1A‐SLC7A11 Axis‐Mediated Ferroptosis Defense

Advanced Science, EarlyView.
This study identifies the mechanosensor PIEZO1 as a key factor in promoting acute myeloid leukemia progression and uncovers a ferroptosis defense system mediated by PIEZO1‐HIF1A‐SLC7A11 axis that is essential for leukemia stem cell maintenance. This ferroptotic defense system may represent a unique vulnerability for leukemia stem cells, providing a ...
Tiantian Zhang, Ziyan Cao, Kexin Gao, Shuxin Yao, Yanbing Zheng, Manman Cui, Rong Yin, Guoqiang Han, Jin Hu, Chengyi Wang, Haojian Zhang   +10 more
wiley   +1 more source

Critical Role of Sensitized Serum in Rejection of Allogeneic Bone Marrow Cells

Turkish Journal of Hematology, 2014
OBJECTIVE: Humoral immunity has been clearly implicated in solid organ transplantation, but little is known about the relationship between humoral immunity and hematopoietic stem cell transplantation.
Lu Hong Xu, Jian Pei Fang, Wen Jun Weng, Hong Gui Xu   +3 more
doaj   +1 more source

GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. [PDF]

, 2019
We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy-requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival ...
Abdel-Azim, Hisham, Ahmed, Ibrahim, Aljurf, Mahmoud, Alousi, Amin M., Arora, Mukta, Askar, Medhat, Auletta, Jeffery J., Bhatt, Vijaya, Bredeson, Christopher, Chhabra, Saurabh, Couriel, Daniel R., Diaz, Miguel Angel, Gadalla, Shahinaz, Gajewski, James, Gale, Robert Peter, Gergis, Usama, Hematti, Peiman, Hemmer, Michael T., Hildebrandt, Gerhard C., Holtan, Shernan G, Inamoto, Yoshihiro, Khandelwal, Pooja, Kitko, Carrie, MacMillan, Margaret L., Majhail, Navneet, Marks, David I., Mehta, Parinda, Mehta, Rohtesh S., Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Pidala, Joseph, Prestidge, Tim, Qayed, Muna, Rangarajan, Hemalatha, Ringden, Olle, Saad, Ayman, Savani, Bipin N., Schultz, Kirk R., Seo, Sachiko, Shah, Ami, Shah, Niketa, Solh, Melhem, Spellman, Stephen R., Spitzer, Thomas, Szer, Jeffrey, Teshima, Takanori, Verdonck, Leo F, Wagner, John, Wang, Tao, Weisdorf, Daniel J., Williams, Kirsten M., Wirk, Baldeep, Yared, Jean A.   +53 more
core   +2 more sources

Natural History of Chronic Kidney Disease in Sickle Cell Disease

American Journal of Hematology, EarlyView.
ABSTRACT Kidney complications, referred to as nephropathy, develop early in sickle cell disease (SCD). In addition to its known morbidity, abundant data show that chronic kidney disease (CKD) is associated with an increased mortality risk in SCD. Increasing evidence suggests that the natural history of SCD nephropathy is progressive. Initial glomerular
Kenneth I. Ataga
wiley   +1 more source

Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner

Swiss Medical Weekly, 2012
The first hematopoietic stem cell transplantation (HSCT), the replacement of the hematopoietic system, by hematopoietic stem cells from the patient (autologous HSCT) or from another person (allogeneic HSCT), was performed almost 45 years ago.
Jakob R Passweg, Joerg Halter, Christoph Bucher, Sabine Gerull, Dominik Heim, Alicia Rovó, Andreas Buser, Martin Stern, André Tichelli   +8 more
doaj   +1 more source

Mesenchymal Differentiation and Organ Distribution of Established Human Stromal Cell Lines in NOD/SCID Mice [PDF]

, 2001
Two human stromal cell lines were established previously from bone marrow-derived primary long-term cultures by immortalization using the SV40 large T antigen and cellular cloning. After irradiation, the fibroblast-like cell lines L87/4 and L88/5 support
Huss, Ralf, Meissner, Petra, Moosmann, Sabine, Sagebiel, Sabine, Thalmeier, Karin, Wiest, Irmgard   +5 more
core   +1 more source

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

American Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on ...
Fangfang Yan, Yang Liu, Heng‐Huan Lee, Wei Wang, Joseph McIntosh, Yijing Li, Jovanny Vargas, Yue Fei, Sairah Ahmed, Lukas M. Simon, Michael Wang   +10 more
wiley   +1 more source

Direct admission to the intensive care unit from the emergency department and mortality in critically ill hematology patients [PDF]

, 2019
Background: The aim of this study was to assess the benefit of direct ICU admission from the emergency department (ED) compared to admission from wards, in patients with hematological malignancies requiring critical care.
Azoulay, Elie, Benoit, Dominique, Bruneel, Fabrice, Chevret, Sylvie, Demoule, Alexandre, Kouatchet, Achille, Lebert, Christine, Lemiale, Virginie, Meert, Anne-Pascale, Mirouse, Adrien, Mokart, Djamel, Nyunga, Martine, Perez, Pierre, Peyrony, Olivier, Pène, Frédéric   +14 more
core   +2 more sources

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

American Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, Marc Michel, Carlo Visco, Michael Fillitz, George Kannourakis, Maria Bruna Greve, Moritz Kleemiss, Johan Cid, Andrea Patriarca, Laura Pavan, Arbana Dizdari, Nilla Maschio, Antonella Sau, Cinzia Bitetti, Riccardo Mario Colombo, Luigi Curreli, Dorela Lame, Uros Markovic, Fabrizio Pappagallo, Giacinto Luca Pedone, Davide Rapezzi, Vincenzo Sammartano, Nicola Tumedei, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Antonio De Vivo, Francesco Lanza, Fabrizio Vianello, Esther N. Oliva, Catherine Broome, Francesco Passamonti, Ulrich Jaeger, Bernd Jilma, Guillaume Moulis, Wilma Barcellini   +38 more
wiley   +1 more source